Tezepelumab reduces steroid dependence in severe asthma patients

Michael Wechsler, MD, lead author on the study and director of the Cohen Family Asthma Institute at National Jewish HealthLong-term oral corticosteroid use can have devastating consequences for patients, including diabetes, osteoporosis, cardiovascular disease and significant impacts on quality of life. These findings are important because they show that patients with severe asthma treated with tezepelumab may be able to substantially reduce their dependence on oral steroids without sacrificing asthma control."

Over the 28-week treatment period, 69% of patients receiving tezepelumab achieved at least a 50% reduction in oral corticosteroid dose compared to 44% of patients receiving the placebo. In addition, 35% of patients treated with tezepelumab were able to completely stop use of oral corticosteroids, compared to 21% in the placebo group.

Source:

National Jewish Health

Journal reference: